Image by Wyman Meinzer

Board of Directors 

Warren Huff   President and CEO of Reata Pharmaceuticals

Mr. Huff is the founding president and chief executive officer of Reata Pharmaceuticals. Mr. Huff was previously the Chief Executive Officer of Ergo Science Corporation, a biopharmaceutical company based in Boston, Massachusetts, that developed neurotransmitter-modulating drugs for the treatment of type 2 diabetes and obesity. Mr. Huff joined Ergo as its first business executive and, under his leadership, Ergo progressed from seed capital to initial public offering in 39 months. Prior to his work with Ergo, Mr. Huff was a senior partner at Dallas law firm, Johnson & Gibbs. Mr. Huff received a B.B.A. magna cum laude from the University of Texas at Austin and a J.D. from Southern Methodist University.

James Bass   Ojai Goliad, LLC

Mr. Bass is a Co-founder and Principal of Ojai Goliad, LLC. Mr. Bass was previously an executive director of an Asian regional investment bank based in Hong Kong. Prior to that he was an attorney over a 9 year period with Gibson, Dunn & Crutcher LLP in both California and Hong Kong and served as a managing partner of the firm's Hong Kong office in the mid 1990s. Mr. Bass graduated with a B.A. degree from Yale University and obtained his J.D. degree from Stanford University. 

R. Kent McGaughy, Jr.   CPMG, Inc.

Mr. McGaughy is a partner in CPMG, Inc. Prior to joining CPMG's predecessor, Cardinal Investment Company in 1997, Mr. McGaughy worked in mergers and acquisitions at Simmons & Company International. Mr. McGaughy currently serves on the boards of several private companies. He received his B.A. from The University of Texas (summa cum laude and member of Phi Beta Kappa) and his M.B.A. from Harvard Business School.

Jack B. Nielsen   Novo Ventures

Mr. Nielsen is a Partner with Novo Ventures, a life science investment organization associated with Novo Nordisk. In this capacity, he is currently or has in the past been on board of directors of Panacos Pharmaceuticals, Cell Biosciences, NeoMend, Mediquest, CardioOptics, Inc. and Protein Forest. Prior to joining the venture organization, Mr. Nielsen held various management positions within Novo Nordisk.  He received his MSc from the Technical University of Denmark and his Masters in Management of Technology from the Center for Technology, Economics, and Management. 

Edward W. “Rusty” Rose   Cardinal Investment Company, Inc

Mr. Rose founded Cardinal Investment Company, Inc. in 1973, and is the firm's President.  Mr. Rose serves on the boards of several private companies, and is on the board of Drew Industries, Inc. (NYSE:  DW).  Mr. Rose is the former Co-managing Partner of the Texas Rangers. He received his B.S. from The University of Texas and his M.B.A. from Harvard Business School.

Dennis Stone, M.D.   Remeditex Ventures

Dr. Stone is Chief Scientific Officer and a Director of Remeditex Ventures. He joined Remeditex from UT Southwestern Medical Center (UTSW) where he was Professor of Internal Medicine, Physiology, and Biochemistry. He served as the Vice President of Technology Development since 1998. During his tenure, Dr. Stone and his team created over $100M in and launched six start-up biotechnology companies that collectively raised over $500 million in financing. Dr. Stone has participated on the board of directors of Eliance Biotechnologies, Inc., Myogen, Inc., miRagen Therapeutics, Inc., MacroGenics, Inc., and Reata Pharmaceuticals, Inc. In addition, he served as the Chairman of the U.T. Regents' Technology Transfer Commission and he was vice chairman of the board of the Texas Emerging Technology Fund's Life Science Commercialization Center. Dr. Stone has received his undergraduate training in the Plan II at The University of Texas at Austin and his medical degree from UTSW.

Nancy Wysenski  

Ms. Wysenski served as the Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals from 2009 to 2012. In this role, she built out the commercial organization from 40 to almost 400 employees and successfully launched Vertex's first two products. INCIVEK sales reached $1 billion in less than a year, faster than any product in pharma history. Six months later, KALYDECO was launched as an orphan drug for the treatment of Cystic Fibrosis. Prior to joining Vertex, Ms. Wysenski held the position of Chief Operating Officer at Endo Pharmaceuticals, where she led sales, marketing, commercial operations, supply chain management, human resources and various business development initiatives. Prior to her role at Endo, Ms. Wysenski was a co-founder of EMD Pharmaceuticals, Inc., the North American subsidiary of Merck KGaA, where she held various leadership positions, including the role of President and CEO from 2001 to 2006 and Vice President of Commercial from 1999 to 2001. From 1984 to 1998, Ms. Wysenski held several sales-focused roles at major pharmaceutical companies, including Vice President of Field Sales for Astra Merck, Inc.